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Abstract
In 2005 the World Health Organisation (WHO) asked its Advisory Committee on Health Research
(ACHR) for advice on ways in which WHO can improve the use of research evidence in the
development of recommendations, including guidelines and policies. The ACHR established the
Subcommittee on the Use of Research Evidence (SURE) to collect background documentation and
consult widely among WHO staff, international experts and end users of WHO recommendations
to inform its advice to WHO. We have prepared a series of reviews of methods that are used in
the development of guidelines as part of this background documentation. We describe here the
background and methods of these reviews, which are being published in Health Research Policy and
Systems together with this introduction.
Background
In May of 2005 the 58th World Health Assembly passed a
resolution requesting the Director-General "to undertake
an assessment of WHO's internal resources, expertise and
activities in the area of health research, with a view to develop-
ing a position paper on WHO's role and responsibilities in the
area of health research, and to report through the Executive
Board to the next World Health Assembly." Related to these
resolutions, WHO has asked the Advisory Committee on
Health Research (ACHR) for advice on ways in which
WHO can improve the use of research evidence in the
development of recommendations, guidelines and poli-
cies.
The ACHR established a subcommittee to collect back-
ground documentation and consult widely among WHO
staff, international experts and end users of WHO recom-
mendations to inform this advice. The advice will focus
on processes to ensure that WHO's recommendations are
well informed by the best available research evidence.
These processes range from how WHO sets priorities for
the development of recommendations to how its recom-
mendations are disseminated and implemented, includ-
ing recommendations developed at WHO headquarters in
Geneva, at its regional offices and in countries.
WHO from its inception has focused on research, which is
mandated in its constitution, and has been a leading
player in the global effort to strengthen ties between
research and health development.
Given WHO's position as the world's leading public
health agency, it is essential that the organisation, its lead-
ers and its governing body ensure that its recommenda-
tions and actions are as well informed as possible by the
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best available research evidence. WHO has strived to do
this for over 50 years with much success.
However, major new developments have occurred since
WHO was established that have led governments around
the world to reconsider the methods that they use to
ensure that decisions about health care and public health
are well informed by research evidence. This reflection
and subsequent changes in how recommendations about
health are developed have been driven by recognition of
gaps between available research evidence and what is
done in practice, variations in practice and outcomes, con-
cerns about the quality of health care, and rising health
care costs.
Increasingly governments, professional and consumer
organisations are demanding more rigorous processes to
ensure that health decisions are well informed by the best
available research evidence. The processes, in contrast
with traditional approaches that rely heavily on the opin-
ions of experts, demand systematic and transparent
approaches to access, synthesise and interpret research
evidence; and to integrate that evidence with the other
information, values and judgements to formulate recom-
mendations. The need for more rigorous processes is
underscored by evidence of inconsistencies between the
available evidence and expert recommendations [1,2],
insufficient use of the available evidence [3,4], and other
insufficiencies in how guidelines and recommendations
are developed [5-12]. Similar criticisms have been raised
and calls have been made for better use of research evi-
dence for health care management and policy making, as
well [13-15].
WHO has the opportunity and the mandate to capitalise
on these advances and to assist its member states to do so.
This is essential to ensure that decisions about health are
well informed by research evidence, and that these deci-
sions lead to effective, efficient and equitable actions
towards achieving WHO's goal: the attainment by all peo-
ples of the highest possible level of health.
As part of the background documentation to inform
ACHR's advice to WHO we have prepared a series of
reviews on the following topics:
• Guidelines for guidelines [16]
• Priority setting [17]
• Group composition and consultation process [18]
• Managing conflicts of interest [19]
• Group processes [20]
• Determining which outcomes are important [21]
• Deciding what evidence to include [22]
• Synthesis and presentation of evidence [23]
• Grading evidence and recommendations [24]
• Integrating values and consumer involvement [25]
• Incorporating considerations of cost-effectiveness,
affordability and resource implications [26]
• Incorporating considerations of equity [27]
• Adaptation, applicability and transferability [28]
• Reporting guidelines [29]
• Disseminating and implementing guidelines [30]
• Evaluation [31]
We have used the term 'guidelines' broadly to include a
wide range of recommendations that WHO makes,
including clinical, public health and health policy recom-
mendations. Although much of the literature that we have
reviewed has focused on clinical practice guidelines, we
have tried to incorporate corresponding literature for pub-
lic health guidelines and health policy recommendations.
The reviews are not full systematic reviews, although we
have aimed to be reasonably systematic and transparent
about the methods we have used and the basis for the rec-
ommendations that we have made. For each review we
began with a series of key questions that were vetted
amongst the authors and the ACHR Subcommittee on the
Use of Research Evidence (SURE). The first author of each
review conducted searches for relevant literature and pre-
pared the first draft. The search strategies that were used
are summarised in each review. We did not always con-
duct exhaustive reviews. We tried first to identify existing
systematic reviews that addressed the questions that we
asked and, secondarily, if we did not find a systematic
review, relevant methodological research. When there was
a paucity of research, we have also included some descrip-
tive literature or, in some cases, evidence that was not
directly related to guidelines development.
Each review includes short summaries of what WHO and
other organisations are doing, our key findings in rela-
tionship to each of the questions that we asked, a discus-
sion of those findings and some suggestions for further
work that is needed. Our answers to the key questions that
we asked are summarised in the abstract of each review.Health Research Policy and Systems 2006, 4:12 http://www.health-policy-systems.com/content/4/1/12
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A draft of each review was first discussed and revised by
the authors. The reviews were also circulated to the ACHR
SURE members and discussed by the subcommittee. After
peer review the articles were revised by the authors and
updated if necessary. We are grateful to the editors of
Health Research Policy and Systems for agreeing to publish
these papers in their journal. In addition to benefiting
from their editorial support, this has enabled us to take
advantage of the BioMed Central's open peer review sys-
tem to help ensure the quality of our reviews and advice.
We also believe that these reviews are of wide interest to
other organisations and individuals that are responsible
for developing guidelines or health policy.
In addition to this series of reviews that is being published
in Health Research Policy and Systems, we have conducted
reviews of what WHO is currently doing, using both doc-
ument analyses and interviews and we have conducted a
survey of initiatives around the world that support the use
of research evidence in developing guidelines or health
policy. We have referred to these reports, which are being
published separately, where relevant in the reviews in this
series.
Preliminary advice from the ACHR has already been dis-
cussed with the leadership of WHO. It has been positively
received and, to some extent, is being acted upon already.
Before delivering our final report and advice to WHO, we
will consult with a reference panel and others within and
outside of WHO. We look forward to working with WHO
to help implement this advice. We hope that it will assist
WHO to better serve its member states by ensuring that its
recommendations are well-informed by the best available
research evidence, and by enabling those responsible for
making decisions to make well-informed choices.
Competing interests
ADO and AF work for the Norwegian Knowledge Centre
forthe Health Services, an agency funded by the Norwe-
gian government that produces systematic reviews and
health technology assessments. All three authors are con-
tributors to the Cochrane Collaboration. ADO and HJS
are members of the GRADE Working Group. HJS is docu-
ments editor and chair of the documents development
and implementation committee for the American Tho-
racic Society and senior editor of the American College of
Chest Physicians' Antithrombotic and Thrombolytic Ther-
apy Guidelines.
Authors' contributions
ADO prepared the first draft of this introduction. AF and
HJS contributed to drafting and revising it.
Acknowledgements
We gratefully acknowledge WHO and the Norwegian Knowledge Centre 
forthe Health Services for financial support, the other authors of these 
reviews for their contributions, the other members of the ACHR SURE, 
and all of those who have provided us with feedback on earlier versions of 
this paper and the others in this series. The members of SURE include: 
Andy Haines, Ana Langer, Andy Oxman (chair), Tikki Pang (WHO), Ulysses 
Panisset (WHO), Judith Whitworth (chair of the ACHR).
References
1. Oxman AD, Guyatt GH: The science of reviewing research.
Annals of the New York Academy of Science 1993, 703:125-34.
2. Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC: A com-
parison of results of meta-analyses of randomized control
trials and recommendations of clinical experts. Treatments
for myocardial infarction.  JAMA 1992, 268:240-248.
3. Silagy CA, Stead LF, Lancaster T: Use of systematic reviews in
clinical practice guidelines: case study of smoking cessation.
BMJ 2001, 323:833-36.
4. Vigna-Taglianti F, Vineis P, Liberati A, Faggiano F: Quality of system-
atic reviews used in guidelines for oncology practice.  Annals
of Oncology 2006, 17:691-701.
5. Bradbury J: Storm over WHO-ISH hypertension guidelines.
Lancet 1999, 353:563.
6. Horton R: WHO: the casualties and compromises of renewal.
Lancet 2002, 359:1605-11.
7. Laing R, Waning B, Gray A, Ford N, t Hoen E: 25 years of the
WHO essential medicines lists: progress and challenges.  Lan-
cet 2003, 36:1723-9.
8. McCarthy M: Critics slam draft WHO report on homoeopa-
thy.  Lancet 2005, 366:705.
9. Oxman AD, Lavis JN, Fretheim A: The use of evidence in WHO
recommendations.  Lancet  in press.
10. Shaneyfelt TM, Mayo-Smith MF, Rothwangl J: Are guidelines fol-
lowing guidelines? The methodological quality of clinical
practice guidelines in the peer-reviewed medical literature.
JAMA 1999, 281:1900-5.
11. Grilli R, Magrini N, Penna A, Mura G, Liberati A: Practice guide-
lines developed by specialty societies: the need for a critical
appraisal.  Lancet 2000, 355:103-6.
12. Grol R, Dalhuijsen J, Thomas S ,  V e l d  C ,  R u t t e n  G ,  M o k k i n k  H :
Attributes of clinical guidelines that influence use of guide-
lines in general practice: observational study.  BMJ 1998,
317:858-61.
13. Lavis JN, Posada FB, Haines A, Osei E: Use of research to inform
policymaking.  Lancet 2004, 364:1615-21.
14. Lavis JN, Davies H, Oxman AD, Denis JL, Golden-Biddle K, Ferlie E:
Towards systematic reviews that inform health care man-
agement and policy-making.  J Health Serv Res Policy 2005,
10(Suppl 1):35-48.
15. Sheldon TA: Making evidence synthesis more useful for man-
agement and policy-making.  J Health Serv Res Policy 2005,
10(Suppl 1):1-5.
16. Schünemann HJ, Fretheim A, Oxman AD: Improving the Use of
Research Evidence in Guideline Development: 1. Guidelines
for guidelines.  Health Res Policy Syst 2006.
17. Oxman AD, Schünemann HJ, Fretheim A: Improving the Use of
Research Evidence in Guideline Development: 2. Priority
setting.  Health Res Policy Syst 2006.
18. Fretheim A, Schünemann HJ, Oxman AD: Improving the Use of
Research Evidence in Guideline Development: 3. Group
composition.  Health Res Policy Syst 2006.
19. Boyd E, Bero L: Improving the Use of Research Evidence in
Guideline Development: 4. Managing conflicts  of interes t.
Health Res Policy Syst 2006.
20. Fretheim A, Schünemann HJ, Oxman AD: Improving the Use of
Research Evidence in Guideline Development: 5. Group
processes.  Health Res Policy Syst 2006.
21. Schünemann HJ, Oxman AD, Fretheim A: Improving the Use of
Research Evidence in Guideline Development: 6. Determin-
ing which outcomes are important.  Health Res Policy Syst 2006.
22. Oxman AD, Fretheim A, Schünemann HJ: Improving the Use of
Research Evidence in Guideline Development: 7. Deciding
what evidence to include.  Health Res Policy Syst 2006.
23. Oxman AD, Schünemann HJ, Fretheim A: Improving the Use of
Research Evidence in Guideline Development: 8. Synthesis
and presentation of evidence.  Health Res Policy Syst 2006.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Health Research Policy and Systems 2006, 4:12 http://www.health-policy-systems.com/content/4/1/12
Page 4 of 4
(page number not for citation purposes)
24. Schünemann HJ, Fretheim A, Oxman AD: Improving the Use of
Research Evidence in Guideline Development: 9. Grading
evidence and recommendations.  Health Res Policy Syst 2006.
25. Schünemann HJ, Fretheim A, Oxman AD: Improving the Use of
Research Evidence in Guideline Development: 10. Integrat-
ing values and consumer involvement.  Health Res Policy Syst
2006.
26. Edejer TTT: Improving the Use of Research Evidence in
Guideline Development: 11. Incorporating considerations of
cost-effectiveness, affordability and resource implications.
Health Res Policy Syst 2006.
27. Oxman AD, Schünemann HJ, Fretheim A: Improving the Use of
Research Evidence in Guideline Development: 12. Incorpo-
rating considerations of equity.  Health Res Policy Syst 2006.
28. Schünemann HJ, Fretheim A, Oxman AD: Improving the Use of
Research Evidence in Guideline Development: 13. Adapta-
tion, applicability and transferability.  Health Res Policy Syst 2006.
29. Oxman AD, Fretheim A, Schünemann HJ: Improving the Use of
Research Evidence in Guideline Development: 14. Reporting
guidelines.  Health Res Policy Syst 2006.
30. Fretheim A, Schünemann HJ, Oxman AD: Improving the Use of
Research Evidence in Guideline Development: 15. Dissemi-
nating and implementing guidelines.  Health Res Policy Syst 2006.
31. Oxman AD, Fretheim A, Schünemann HJ: Improving the Use of
Research Evidence in Guideline Development: 16. Evalua-
tion.  Health Res Policy Syst 2006.